Patents
Literature
3 results about "Bombesin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bombesin is a 14-amino acid peptide originally isolated from the skin of the European fire-bellied toad (Bombina bombina). It has two known homologs in mammals called neuromedin B and gastrin-releasing peptide. It stimulates gastrin release from G cells. It activates three different G-protein-coupled receptors known as BBR1, -2, and -3. It also activates these receptors in the brain. Together with cholecystokinin, it is the second major source of negative feedback signals that stop eating behaviour.
A subcellular organelle active targeting imaging probe and a preparation method thereof
The application belongs to the technical field of biological diagnosis, and relates to a subcellular organelle active targeting imaging probe and a preparation method thereof. The subcellular organelle active targeting imaging probe of the application is formed into nanoparticles (NPs) by coupling a fluorescent imaging probe with a special sequence of bombesin peptide and a derivative thereof; on one hand, the NPs can be surface-functionalized with lipophilic cations related to the NPs; on the other hand, the NPs can be passively targeted to tumor sites, and have high permeability and retention effect for solid tumors.
Owner:NINGBO INST OF MATERIALS TECH & ENG CHINESE ACAD OF SCI +1
Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
To provide an improved radiotherapeutic agent for treating a disease associated with abnormal expression of a gastrin-releasing peptide receptor.SOLUTION: Provided is a bombesin-derived compound of formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX includes a radionuclide chelator or trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe or the like, and Xaa2 is Gly or the like. Xaa3 is Leu or the like, and Xaa4 is Pro or the like. A symbol ψ denotes reduced peptide bond between Xaa3 and Xaa4. In the case where Xaa4 is Pro or the like, ψ is CH2-N, or in the case where Xaa4 is Phe or Nle, ψ is CH2 N(R). R is H or a C1-C5 linear or branched alkyl. Use of the compound as a contrast medium or therapeutic agent is also provided.SELECTED DRAWING: None
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY
Application of protostemonine in preparation of medicine for treating acute pancreatitis
PendingCN121154646ADigestive systemHeterocyclic compound active ingredientsAmylaseInflammatory factors
The invention relates to the technical field of biological pharmacy, and particularly discloses application of protostemonine or pharmaceutical salt thereof in preparation of a medicine for preventing or treating acute pancreatitis. The establishment of an acute pancreatitis animal model induced by combination of rain frog element and LPS proves that protostemonine can significantly reduce the activity of model mouse serum amylase and lipase, alleviate pancreatic tissue pathological damage, inhibit the activity of pancreatic tissue myeloperoxidase (MPO) and mRNA expression of inflammatory factors IL-1beta, IL-6 and TNF-alpha, and inhibit pancreatic tissue myeloperoxidase (MPO). Therefore, local inflammation and tissue damage of the pancreas are effectively relieved. An in-vitro cell experiment further verifies the biological activity of the compound. The invention provides a new drug choice for clinical treatment of acute pancreatitis, and has a good development prospect. The medicine can be prepared into various dosage forms such as injections, tablets, capsules and the like, and can be combined with other anti-inflammatory medicines for use.
Owner:SHANGHAI TONGREN HOSPITAL